dabrafenib: Clinical Trials

4 trials of dabrafenib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 44Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow dabrafenib: new trials by email Literature Review of dabrafenib trials Research Report on dabrafenib

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Dabrafenib, Trametinib, Selpercatinib - Thyroid Neoplasms
Phase 4Not yet recruitingFujian Medical University3352025-07-012025-06-08
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
dabrafenib plus trametinib with or without PD-1 antibody, entrectinib or larotrectinib with or without anti-PD-1 antibdoy, pralsetinib or selpercatinib with or without anti-PD-1 antibdoy - Advanced Thyroid Cancer Patients Who Received Target Therapy
Phase 4RecruitingFudan University8002020-01-012025-08-14
Pediatric Long-Term Follow-up and Rollover Study
dabrafenib, trametinib - Diffuse Astrocytoma, Anaplastic Astrocytoma
Phase 4Active not recruitingNovartis Pharmaceuticals1632019-11-042026-08-27
Dabrafenib and/or Trametinib Rollover Study
dabrafenib, trametinib - Melanoma, Non Small Cell Lung Cancer
Phase 4RecruitingNovartis Pharmaceuticals1002018-01-262026-11-10

Conditions studied

Glioma (2)  ·  Astrocytoma (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Ganglioglioma (1)  ·  Ganglioneuroma (1)  ·  Glioblastoma (1)  ·  Histiocytosis, Langerhans-Cell (1)  ·  Lung Neoplasms (1)  ·  Melanoma (1)  ·  Neuroblastoma (1)  ·  Neurocytoma (1)  ·  Neurofibroma, Plexiform (1)  ·  Neurofibromatosis 1 (1)  ·  Oligodendroglioma (1)  ·  Thyroid Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (2)  ·  Fudan University (1)  ·  Fujian Medical University (1)

Countries

China (3)  ·  Argentina (2)  ·  Canada (2)  ·  Czechia (2)  ·  Denmark (2)  ·  France (2)  ·  Germany (2)  ·  Japan (2)  ·  Netherlands (2)  ·  Russia (2)  ·  Spain (2)  ·  United States (2)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)

Top investigators

Dongmei Ji, M.D (1)  ·  Qinghai Ji, M.D (1)  ·  Yansong Lin, M.D (1)  ·  Yu Wang, M.D (1)

NIH funding

2023 (2)